IUGR may block the proliferative Bmpr1a/Bmpr2 pathways during the intrauterine phase, while it is shifted to pro-proliferative signaling by postnatal reduction of Bmpr1b as an attempt to promote vascularisation and compensate for the intrauterine growth restriction32. The gene discussed is BMPR1A; the disease is fetal growth restriction.